Axsome Therapeutics Inc
Axsome Therapeutics Inc (AXSM) Historical Volatility
AXSM's 30 day historical volatility is 50.83%, in the 84th percentile of readings over the past year. This is a high percentile, meaning Axsome Therapeutics Inc shares have swung far more than usual. AXSM's 30 day implied volatility sits at 58.14%, with an IV Rank of 85.71%, leaving IV 7.31 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 20, 2026.
Read more
Tracking AXSM historical volatility helps you see how much Axsome Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, AXSM's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor AXSM 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. AXSM's 30 day historical volatility, or AXSM HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing AXSM's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 20, 2026
As of Nov 20, 2026
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →